199 related articles for article (PubMed ID: 18386289)
1. Structural characterization and anti-angiogenic properties of prostate-specific antigen isoforms in seminal fluid.
Mattsson JM; Valmu L; Laakkonen P; Stenman UH; Koistinen H
Prostate; 2008 Jun; 68(9):945-54. PubMed ID: 18386289
[TBL] [Abstract][Full Text] [Related]
2. Selective recognition of enzymatically active prostate-specific antigen (PSA) by anti-PSA monoclonal antibodies.
Michel S; Collomb-Clerc E; Geourjon C; Charrier JP; Passagot J; Courty Y; Deléage G; Jolivet-Reynaud C
J Mol Recognit; 2005; 18(3):225-35. PubMed ID: 15593306
[TBL] [Abstract][Full Text] [Related]
3. Oligosaccharide profiles of the prostate specific antigen in free and complexed forms from the prostate cancer patient serum and in seminal plasma: a glycopeptide approach.
Tajiri M; Ohyama C; Wada Y
Glycobiology; 2008 Jan; 18(1):2-8. PubMed ID: 17956937
[TBL] [Abstract][Full Text] [Related]
4. Separation of enzymatically active and inactive prostate-specific antigen (PSA) by peptide affinity chromatography.
Wu P; Stenman UH; Pakkala M; Närvänen A; Leinonen J
Prostate; 2004 Mar; 58(4):345-53. PubMed ID: 14968435
[TBL] [Abstract][Full Text] [Related]
5. Altered glycosylation pattern allows the distinction between prostate-specific antigen (PSA) from normal and tumor origins.
Peracaula R; Tabarés G; Royle L; Harvey DJ; Dwek RA; Rudd PM; de Llorens R
Glycobiology; 2003 Jun; 13(6):457-70. PubMed ID: 12626390
[TBL] [Abstract][Full Text] [Related]
6. Recombinant prostate specific antigen inhibits angiogenesis in vitro and in vivo.
Fortier AH; Holaday JW; Liang H; Dey C; Grella DK; Holland-Linn J; Vu H; Plum SM; Nelson BJ
Prostate; 2003 Aug; 56(3):212-9. PubMed ID: 12772191
[TBL] [Abstract][Full Text] [Related]
7. Strategy for sensitive and specific detection of molecular forms of PSA based on 2DE and kinetic analysis: a step towards diagnosis of prostate cancer.
Kumar V; Hassan MI; Singh AK; Dey S; Singh TP; Yadav S
Clin Chim Acta; 2009 May; 403(1-2):17-22. PubMed ID: 19118539
[TBL] [Abstract][Full Text] [Related]
8. Novel small molecule inhibitors for prostate-specific antigen.
Koistinen H; Wohlfahrt G; Mattsson JM; Wu P; Lahdenperä J; Stenman UH
Prostate; 2008 Aug; 68(11):1143-51. PubMed ID: 18500692
[TBL] [Abstract][Full Text] [Related]
9. Characterization of prostate-specific antigen proteolytic activity on its major physiological substrate, the sperm motility inhibitor precursor/semenogelin I.
Robert M; Gibbs BF; Jacobson E; Gagnon C
Biochemistry; 1997 Apr; 36(13):3811-9. PubMed ID: 9092810
[TBL] [Abstract][Full Text] [Related]
10. Two step procedure for purification of enzymatically active prostate-specific antigen from seminal plasma.
Bindukumar B; Kawinski E; Cherrin C; Gambino LM; Nair MP; Schwartz SA; Chadha KC
J Chromatogr B Analyt Technol Biomed Life Sci; 2004 Dec; 813(1-2):113-20. PubMed ID: 15556523
[TBL] [Abstract][Full Text] [Related]
11. Different molecular forms of uncomplexed prostate specific antigen (PSA) show similar immunoreactivities.
Chu LF; Chen Z; Stamey TA
J Urol; 1999 Jun; 161(6):2009-12. PubMed ID: 10332491
[TBL] [Abstract][Full Text] [Related]
12. Antiangiogenic properties of prostate-specific antigen (PSA).
Mattsson JM; Laakkonen P; Stenman UH; Koistinen H
Scand J Clin Lab Invest; 2009; 69(4):447-51. PubMed ID: 19551556
[TBL] [Abstract][Full Text] [Related]
13. Anti-angiogenic activity of PSA-derived peptides.
Chadha KC; Nair B; Godoy A; Rajnarayanan R; Nabi E; Zhou R; Patel NR; Aalinkeel R; Schwartz SA; Smith GJ
Prostate; 2015 Sep; 75(12):1285-99. PubMed ID: 25963523
[TBL] [Abstract][Full Text] [Related]
14. Carbohydrate structure and differential binding of prostate specific antigen to Maackia amurensis lectin between prostate cancer and benign prostate hypertrophy.
Ohyama C; Hosono M; Nitta K; Oh-eda M; Yoshikawa K; Habuchi T; Arai Y; Fukuda M
Glycobiology; 2004 Aug; 14(8):671-9. PubMed ID: 15044396
[TBL] [Abstract][Full Text] [Related]
15. Identification of precursor forms of free prostate-specific antigen in serum of prostate cancer patients by immunosorption and mass spectrometry.
Peter J; Unverzagt C; Krogh TN; Vorm O; Hoesel W
Cancer Res; 2001 Feb; 61(3):957-62. PubMed ID: 11221890
[TBL] [Abstract][Full Text] [Related]
16. Different glycan structures in prostate-specific antigen from prostate cancer sera in relation to seminal plasma PSA.
Tabarés G; Radcliffe CM; Barrabés S; Ramírez M; Aleixandre RN; Hoesel W; Dwek RA; Rudd PM; Peracaula R; de Llorens R
Glycobiology; 2006 Feb; 16(2):132-45. PubMed ID: 16177264
[TBL] [Abstract][Full Text] [Related]
17. Structural characteristics of the N-glycans of two isoforms of prostate-specific antigens purified from human seminal fluid.
Okada T; Sato Y; Kobayashi N; Sumida K; Satomura S; Matsuura S; Takasaki M; Endo T
Biochim Biophys Acta; 2001 Feb; 1525(1-2):149-60. PubMed ID: 11342264
[TBL] [Abstract][Full Text] [Related]
18. Purification and characterization of different molecular forms of prostate-specific antigen in human seminal fluid.
Zhang WM; Leinonen J; Kalkkinen N; Dowell B; Stenman UH
Clin Chem; 1995 Nov; 41(11):1567-73. PubMed ID: 7586544
[TBL] [Abstract][Full Text] [Related]
19. Proteomic profiling of the effect of prostate-specific antigen on prostate cancer cells.
Bindukumar B; Schwartz S; Aalinkeel R; Mahajan S; Lieberman A; Chadha K
Prostate; 2008 Oct; 68(14):1531-45. PubMed ID: 18646040
[TBL] [Abstract][Full Text] [Related]
20. Characterization of prostate-specific antigen binding peptides selected by phage display technology.
Ferrieu-Weisbuch C; Michel S; Collomb-Clerc E; Pothion C; Deléage G; Jolivet-Reynaud C
J Mol Recognit; 2006; 19(1):10-20. PubMed ID: 16312021
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
